ProBioGen Partners with DIOSynVax for Trivalent HF Vaccine Production

• ProBioGen and DIOSynVax collaborate to manufacture DIOS-HFVac3, a trivalent hemorrhagic fever vaccine targeting Ebola, Marburg, and Lassa viruses.

• The vaccine will be produced using ProBioGen’s advanced industrial platform and is part of the UK Vaccine Network (UKVN) funded by the Department of Health and Social Care.

ProBioGen, the Berlin-based Contract Development & Manufacturing Organisation (CDMO) has announced a significant partnership with DIOSynVax Ltd to manufacture DIOS-HFVac3, a trivalent hemorrhagic fever (HF) vaccine targeting diseases caused by Ebola, Marburg, and Lassa viruses.

The novel vaccine, developed in collaboration with Prof. Wagner’s team at the University of Regensburg, has shown promising pre-clinical efficacy in challenge studies in animal models. ProBioGen’s MVA CR19 vector will deliver the three HF vaccine antigens, demonstrating the company’s commitment to innovative vaccine delivery solutions.

DIOS-HFVac3 will be manufactured on ProBioGen’s cutting-edge industrial platform, which includes the company’s proprietary AGE1.CR.pIX suspension cell line, chemically defined media, and advanced scalable production and purification processes. This platform is designed to produce a broad range of viral vaccines, emphasizing ProBioGen’s expertise in biopharmaceutical manufacturing.

The partnership between ProBioGen and DIOSynVax is supported by the UK Vaccine Network (UKVN), a UK Aid program focused on developing vaccines for diseases with epidemic potential in low and middle-income countries (LMICs). Dr. Volker Sandig, Chief Scientific Officer at ProBioGen, expressed the company’s commitment to advancing robust and resilient biopharmaceutical solutions for global health challenges.

Dr. Lutz Hilbrich, CEO of ProBioGen, highlighted the company’s dedication to pioneering technologies and expanding its service value chain through transformative collaborations like the one with DIOSynVax. This sentiment was echoed by DIOSynVax’s CEO Prof. Jonathan Heeney, who emphasized ProBioGen’s role as a trusted partner in delivering life-saving therapies to developing countries, particularly in Africa.